Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United StatesBusiness Wire • 05/21/25
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular LensBusiness Wire • 05/07/25
Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE RehospitalizationAccesswire • 05/06/25
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock DownZacks Investment Research • 05/01/25
Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX SystemAccesswire • 04/29/25
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 04/24/25
Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling ProgramsBusiness Wire • 04/21/25
U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against NorwichAccesswire • 04/17/25
Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship ProgramAccesswire • 04/10/25
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne VulgarisAccesswire • 04/09/25
Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion OpportunitySeeking Alpha • 04/05/25
Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness MonthAccesswire • 04/02/25